NCT06656624
Efficacy and Safety of Ribociclib Combined With AI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Progression Free Survival
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Secondary (7)
Progression Free Survival2
Time to treatment failure
Overall response rate
Overall survival(OS)
Time To Response
Show 2 moreShow less
Clinical benefit rate
Frequency/severity of adverse events
Arms and interventions
physician's choice of chemotherapy sequential Ribociclib combined with AI±OFSActive comparator
Ribociclib combined with AI±OFSExperimental
Drugs: Ribociclib combined with AI±OFS, physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS
Sites
1 site in 1 country
- Jiangsu Provincial People's HospitalNanjing, Jiangsu, China